ACRIA Studies in Progress
Fall 2003/Winter 2004
This trial will study whether people on their first HAART regimen who take their drugs two or more times a day can switch to a once-daily regimen. People in the trial will either remain on their current medications, or switch to Zerit XR, Epivir and Sustiva (ZEST) taken once daily. They will visit ACRIA 9 times over 11 months. All blood tests, study visits, and study medications (Zerit XR, Epivir and Sustiva), as well as medications from the Standard Of Care arm that are manufactured by the sponsor, will be provided at no charge to the participants. Prescriptions will be written for any other anti-HIV drug. You are eligible if you are HIV-positive, age 18 or over, and on an initial HAART regimen (one or more NRTIs, at least one agent must have a twice-daily dosing schedule, and no NNRTI in the past or in current regimen) with a viral load below 50. Study participants will be reimbursed $25 for each visit.
To enroll, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at 212-924-3934 ext. 124.
This trial, which is closed to new enrollment, continues to study the safety and efficacy of tipranavir (a protease inhibitor) boosted with low-dose ritonavir in people who have taken multiple antiretrovirals. All patients must have taken drugs from each of the three antiretroviral classes, have taken at least two protease inhibitors, have a viral load over 1,000, and must currently be taking a protease inhibitor.
We have completed the first phase of enrollment for this study. Results from this study will be available soon on our Web site.
ACRIA is currently establishing a large cohort to conduct research on HIV-positive people over 50. If you would like to be included in this database, please contact Salone Howard at 212-924-3934 x105 or email firstname.lastname@example.org.
People in this study were interviewed about treatments other than antiretrovirals, such as supplements, exercise, acupuncture, herbal remedies, as well as who provides the treatments, how often they use them, and if they feel they are helpful. To qualify, people must have been HIV positive, using HAART for at least a year, and be using other treatments for HIV/AIDS. If you are interested in participating in future studies, contact Salone Howard at 212-924-3934 x105 or email email@example.com.
This Internet survey studies the extent to which HIV service providers may benefit from HIV prevention programs or programs designed to assist them in other areas of their job. Visit www.acria.org to participate.
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.